Compare Crispr Therapeutics AG (CRSP) vs Rent the Runway Inc (RENT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Rent the Runway Inc — how do they compare? Crispr Therapeutics AG trades at $53.89 (market cap $4.88B), while Rent the Runway Inc trades at $1.74 (market cap $61.75M). The key difference: Crispr Therapeutics AG is far larger — about 79× Rent the Runway Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Rent the Runway Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Rent the Runway Inc for 56 Days on average.
| CRSP | RENT | |
|---|---|---|
Market Cap | $4.88B | $61.75M |
Volume | 2,861,747 | 193,323 |
Sector | Health | Consumer Cyclical |
52-Week High | $74.92 | $9.39 |
52-Week Low | $44.34 | $1.55 |
Typical Hold Time | 77 Days | 56 Days |
Enterprise Value | $3.30B | $228.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
RENT trades at $1.765, up 5.06% today, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported revenue of $306.20M in 2025 with improving net loss margins, yet negative shareholder equity and high debt-to-asset ratios persist. Recent news includes a CEO appointment and multiple law firm investigations into investor claims, creating a complex sentiment backdrop.
The outlook remains challenged by financial instability and legal scrutiny, though analyst consensus leans buy with no sell ratings. Key risks include high leverage and ongoing losses, while potential upside hinges on execution of growth initiatives and margin improvement. Investors face significant volatility amid restructuring efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →
